Expanding Domestic Market Share in Focus Product Areas

「In Japan's orthopaedic joint replacement market, some medical institutions declined to adopt the Company's products from the fourth quarter onward due to the impact of reported incidents, resulting in a decline in cases acquired. Consequently, domestic revenue in this field was ¥4,904 million, down 6.4% from the previous consolidated fiscal year.」

「To address growing medical needs, we will continue launching new products that contribute to improved treatment outcomes, while seeking to increase the number of cases won and raise our market share.」

「In Japan's orthopaedic joint replacement market, the number of THA cases acquired increased as new facilities were added, maintaining double-digit growth. By contrast, BHA declined slightly from the high level recorded in the same period of the previous year, while TKA declined year on year. As a result, domestic revenue in this field was ¥2,421 million, up 2.0% year on year.」

「In Japan's orthopaedic joint replacement market, the number of cases acquired for bipolar hip arthroplasty (BHA), including the HA-coated artificial hip product Entrada Hip Stem and the new Promontory Hip Stem, increased, and total BHA revenue grew at a double-digit rate. By contrast, revenue from total hip arthroplasty (THA) declined as the number of cases acquired decreased. The number of cases acquired for total knee arthroplasty (TKA) also declined, resulting in lower total TKA revenue. Consequently, domestic revenue in this field was ¥2,373 million, up 0.5% year on year.」

「In Japan, despite the impact of reimbursement price cuts implemented in April 2023 and January 2024, the increase in cases acquired resulted in revenue of ¥13,004 million, up ¥647 million, or 5.2%, from the previous consolidated fiscal year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」

「In Japan, despite the impact of the reimbursement price cut implemented in April 2023, the increase in cases acquired resulted in revenue of ¥9,541 million, up ¥560 million, or 6.2%, year on year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」

「In Japan, despite the impact of the reimbursement price cut implemented in April 2023, the increase in cases acquired resulted in revenue of ¥6,129 million, up ¥324 million, or 5.6%, year on year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」

「In Japan, despite the impact of the reimbursement price cut implemented in April 2023, the increase in cases acquired resulted in revenue of ¥3,055 million, up ¥121 million, or 4.1%, year on year, after deducting part of selling expenses following the application of the Accounting Standard for Revenue Recognition.」

「In Japan, revenue per case declined due to the reimbursement price cut in April 2022, but the number of cases acquired increased year on year, resulting in revenue of ¥8,980 million, up ¥242 million, or 2.8%, year on year.」

「In Japan, reimbursement price cuts caused revenue per case to decline, but the number of cases acquired increased from the same quarter of the previous year, resulting in revenue of ¥5,805 million, up ¥339 million, or 6.2%, year on year.」

「In Japan, case volumes recovered from the same quarter of the previous year, which was affected by COVID-19, and revenue was ¥2,933 million, up ¥210 million, or 7.7%, year on year.」

「Although sales activities in Japan were restricted due to the impact of COVID-19, the number of cases recovered by maintaining good relationships with existing customers, and revenue rose to ¥8,738 million, up ¥655 million, or 8.1%, year on year.」

「Although sales activities in Japan remained restricted due to the impact of COVID-19, the number of cases gradually recovered, and revenue rose to ¥5,466 million, up ¥398 million, or 7.9%, year on year, exceeding the level of the same quarter two years earlier, before the COVID-19 pandemic.」

「Although sales activities in Japan remained restricted due to the impact of COVID-19, the number of cases gradually recovered, and revenue rose to ¥2,722 million, up ¥322 million, or 13.4%, year on year, returning to the level of the same quarter two years earlier, before the COVID-19 pandemic.」

「Amid the global spread of COVID-19, domestic revenue in Japan increased 0.3% year on year to ¥8,082 million.」

「Revenue declined as the number of cases decreased due to the impact of COVID-19 in Japan and the United States. Domestic revenue in Japan declined 3.5% year on year to ¥5,067 million.」

「Revenue declined as the number of cases decreased due to the impact of COVID-19 in Japan and the United States. Domestic revenue in Japan declined 8.0% year on year to ¥2,400 million.」

「In Japan, reimbursement prices were reduced in stages in April 2019. In the osteosynthesis products field, the number of cases declined due to an unusually warm winter, and the shortage of OM Femoral Nail System III (product name: ASULOCK) inventory was not resolved. In addition, the impact of COVID-19 began to emerge toward the end of the fourth quarter. Nevertheless, as sales in the artificial joint and spinal fixation products fields performed steadily, domestic revenue increased 7.5% from the previous consolidated fiscal year to ¥10,921 million.」

「Total selling, general and administrative expenses increased 6.1% year on year to ¥3,980 million in both Japan and the United States, due mainly to higher salaries and allowances resulting from increased staffing to strengthen sales capabilities, higher depreciation resulting from an increase in loaned medical instruments for sales expansion of new and existing products since the third quarter of the previous year, higher commissions resulting from increased sales in the United States, and an increase in U.S. selling, general and administrative expenses translated into yen due to the weaker yen. The ratio of selling, general and administrative expenses to revenue also rose to 60.2% from 58.7%.」

「Expanding domestic market share in priority product areas. The Group will seek to expand the share of priority products in growth areas and increase sales of products that provide a stable foundation. To achieve these objectives, it will organize its domestic sales offices into 4 blocks to provide detailed customer support.」

「Expanding domestic market share in priority product areas. The Group will seek to expand the share of priority products in growth areas and increase sales of products that provide a stable foundation. To achieve these objectives, it will organize its domestic sales offices into 4 blocks to provide detailed customer support. It will also establish joint-product and spine-product groups, with teams in eastern and western Japan, to strengthen sales capabilities with an emphasis on specialization.」